Aprogen Medicines Inc. (KRX:007460)
South Korea · Delayed Price · Currency is KRW 2,030.00
+30.00 (1.50%)
Sep 11, 2026, 3:30 PM KST
Aprogen Medicines Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 138,901 | 117,974 | 150,114 | 150,578 | 78,349 | 26,296 |
Revenue Growth | 9.09% | -21.41% | -0.31% | 92.19% | 197.95% | -79.32% |
Gross Profit Gross Profit Growth | 34,593 | 31,171 | 34,295 | 34,198 | 205.9 | -5,217 |
Operating Income Operating Income Growth | -80,386 | -95,571 | -86,807 | -94,970 | -116,944 | -95,807 |
Net Income Net Income Growth | -83,531 | -70,202 | -58,079 | -55,619 | -98,657 | -93,920 |
Earnings Per Share EPS Growth | -4035.31 | -3540.15 | -3379.30 | -3540.00 | -7461.18 | -8125.79 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Pharmaceutical Pharmaceutical Growth | 59,411 |
Semiconductor Business Division Semiconductor Business Division Growth | 9,636 |
Other Sales Other Sales Growth | 496.95 |
Bio Sector Bio Sector Growth | 2,935 |
Metal Sector Metal Sector Growth | 35,579 |
Insulation Business Division Insulation Business Division Growth | 2,423 |
Geothermal Business Division Geothermal Business Division Growth | 7,493 |
Total Total Growth | 117,974 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 43,163 | 50,760 | 43,662 | 40,684 | 47,460 | 19,894 |
Total Debt Total Debt Growth | 181,445 | 187,862 | 113,702 | 124,417 | 90,195 | 452,369 |
Net Cash (Debt) Net Cash Growth | -138,282 | -137,102 | -70,041 | -83,732 | -42,736 | -432,475 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -6680.28 | -6913.76 | -4062.06 | -5318.10 | -3167.42 | -37416.92 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -62,794 | -32,657 | -44,992 | -58,156 | -113,491 | -84,740 |
Capital Expenditures CapEx Growth | -3,988 | -8,994 | -12,671 | -25,514 | -19,610 | -34,392 |
Free Cash Flow Free Cash Flow Growth | -66,781 | -41,651 | -57,662 | -83,669 | -133,101 | -119,132 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 24.91% | 26.42% | 22.85% | 22.71% | 0.26% | -19.84% |
Operating Margin | -57.87% | -81.01% | -57.83% | -63.07% | -149.26% | -364.35% |
Pretax Margin | -98.83% | -120.63% | -65.74% | -63.25% | -147.56% | -453.84% |
Profit Margin | -60.14% | -59.51% | -38.69% | -36.94% | -125.92% | -357.17% |
FCF Margin | -48.08% | -35.30% | -38.41% | -55.57% | -169.88% | -453.05% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 0.32 | 1.82 | 1.47 | 1.56 | 5.10 | 12.76 |